Braveheart Bio investor converts preferred, buys shares
Rhea-AI Filing Summary
Braveheart Bio, Inc. reported that investment entities affiliated with Forbion converted 75,000,000 shares of Series A Preferred Stock into 17,123,287 shares of Common Stock on August 7, 2026, in connection with the closing of the initial public offering, at a 1-for-4.38 conversion rate without additional consideration. On the same date, these Forbion entities also purchased 3,600,000 Common Shares at $18.00 per share in open-market or private transactions. Footnotes state that the management entities may be deemed to have voting and dispositive power over the fund holdings and that each reporting person disclaims Section 16 beneficial ownership except to the extent of its pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 3,600,000 shares
Net Buy
6 txns
Insider
Forbion Growth Opportunities Fund III Cooperatief U.A., Forbion Growth III Management B.V., Forbion Ventures Fund VII Cooperatief U.A., Forbion Ventures VII Management B.V.
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
3,600,000 shs ($64.80M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Stock F1, F2 | 40,000,000 | $0.00 | $0.00 |
| Conversion | Series A Preferred Stock F1, F3 | 35,000,000 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F2 | 9,132,420 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F3 | 7,990,867 | $0.00 | $0.00 |
| Purchase | Common Stock F2 | 1,920,000 | $18.00 | $34.56M |
| Purchase | Common Stock F3 | 1,680,000 | $18.00 | $30.24M |
Holdings After Transaction:
Series A Preferred Stock — 0 contracts (Direct);
Series A Preferred Stock — 0 contracts (Indirect, By Forbion Ventures Fund VII Cooperatief U.A.);
Common Stock — 11,640,546 shares (Direct);
Common Stock — 10,185,478 shares (Indirect, By Forbion Ventures Fund VII Cooperatief U.A.)
Footnotes (3)
- F1. Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.
- F2. Forbion Growth III Management B.V. ("Forbion Growth III Management") is the director of Forbion Growth Opportunities Fund III Cooperatief U.A. (the "Forbion Growth III") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Growth III. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
- F3. Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.
Key Figures
Preferred shares converted: 75,000,000 shares
Common shares received on conversion: 17,123,287 shares
Conversion ratio: 1-for-4.38
+2 more
5 metrics
Preferred shares converted
75,000,000 shares
Series A Preferred Stock converted on August 7, 2026
Common shares received on conversion
17,123,287 shares
Common Stock issued upon 1-for-4.38 conversion of Series A Preferred
Conversion ratio
1-for-4.38
Each Series A Preferred share converted into Common Stock at IPO closing
Common shares purchased
3,600,000 shares
Open-market or private purchases on August 7, 2026
Purchase price
$18.00 per share
Price paid for 3,600,000 Common shares
Key Terms
Series A Preferred Stock, initial public offering, derivative security, Section 16 beneficial ownership
4 terms
Series A Preferred Stock financial
"Each share of Series A Preferred Stock automatically converted into Common Stock"
Series A preferred stock is a type of ownership share in a company that gives investors certain advantages, such as priority in receiving profits or getting their money back if the company is sold or goes bankrupt. It is often issued during early funding stages to attract investors by offering more security than common shares. This stock matters to investors because it provides a safer way to invest while still holding potential for future gains.
initial public offering financial
"Upon the closing of the Issuer's initial public offering, each share of Series A"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
derivative security financial
"transaction_code_description":"Conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Section 16 beneficial ownership regulatory
"Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Braveheart Bio (BRVE) report on August 7, 2026?
On August 7, 2026, affiliated Forbion funds converted 75,000,000 Series A Preferred shares into 17,123,287 Common shares and purchased 3,600,000 additional Common shares at $18.00 per share.
What common stock purchases by Forbion were disclosed for Braveheart Bio (BRVE)?
The report shows Forbion-related entities purchased 3,600,000 shares of Braveheart Bio Common Stock on August 7, 2026 at a price of $18.00 per share, in open-market or private transactions.
Were the Braveheart Bio (BRVE) insider transactions under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and the footnotes do not state that these Braveheart Bio transactions were executed under a Rule 10b5-1 trading plan.
Did the Series A Preferred Stock of Braveheart Bio (BRVE) have an expiration date?
The disclosure notes that the Series A Preferred Stock had no expiration date before it automatically converted into Common Stock upon the closing of Braveheart Bio’s initial public offering.
AI-generated analysis. How Rhea-AI works. Not financial advice.
